Trial Profile

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANAVEX3-71 (Primary)
Indications Schizophrenia
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use

01 May 2025 According to an Anavex Life Sciences media release, study has enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B., the company expects to report top-line data from the study in the second half of 2025.
30 Apr 2025 Planned End Date changed from 15 May 2025 to 30 Jun 2025.
30 Apr 2025 Planned primary completion date changed from 15 May 2025 to 30 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com